Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms

[1]  G. Gessa,et al.  The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex , 2000, Molecular Psychiatry.

[2]  M. Teitler,et al.  Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[3]  J. Leander,et al.  A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon , 2000, Behavioural pharmacology.

[4]  Leander Jd,et al.  A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon. , 2000 .

[5]  J. Neumaier,et al.  Clozapine downregulates 5-hydroxytryptamine6 (5-HT6) and upregulates 5-HT7 receptors in HeLa cells , 2000, Neuroscience Letters.

[6]  M. Wood,et al.  Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT(7) receptor. , 2000, European journal of pharmacology.

[7]  G. Aghajanian,et al.  Serotonin model of schizophrenia: emerging role of glutamate mechanisms , 2000, Brain Research Reviews.

[8]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[9]  J. Krystal,et al.  Symptom provocation studies in psychiatric disorders: scientific value, risks, and future , 1999, Biological Psychiatry.

[10]  W. Carpenter.  The schizophrenia ketamine challenge study debate , 1999, Biological Psychiatry.

[11]  R. Porter,et al.  Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells , 1999, British journal of pharmacology.

[12]  J. Frederick,et al.  Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain , 1999, Schizophrenia Research.

[13]  D. Greenblatt,et al.  Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions , 1999, Psychopharmacology.

[14]  B. Roth,et al.  Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo , 1999, Neuroscience.

[15]  S. Potkin,et al.  Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial , 1999, Neuropsychopharmacology.

[16]  S. Tsai,et al.  Serotonin-6 receptor variant (C267T) and clinical response to clozapine. , 1999, Neuroreport.

[17]  M. Millan,et al.  Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO60-0175: a pharmacological analysis , 1999, Neuropharmacology.

[18]  E. Eriksson,et al.  Effects of mCPP on the Extracellular Concentrations of Serotonin and Dopamine in Rat Brain , 1999, Neuropsychopharmacology.

[19]  S. Kapur,et al.  Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.

[20]  G. Tollefson,et al.  Review of recent clinical studies with olanzapine , 1999, British Journal of Psychiatry.

[21]  M. Göthert,et al.  Genetic Variation in Human 5‐HT Receptors: Potential Pathogenetic and Pharmacological Role a , 1998, Annals of the New York Academy of Sciences.

[22]  M. Teitler,et al.  Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.

[23]  R. Schreiber,et al.  Role of 5-HT1B, 5-HT2A and 5-HT2C receptors in the generalization of 5-HT receptor agonists to the ethanol cue in the rat. , 1998, Behavioural pharmacology.

[24]  T. Hijzen,et al.  Discriminative stimulus properties of mCPP: evidence for a 5-HT2C receptor mode of action , 1998, Psychopharmacology.

[25]  H. Grill,et al.  Serotonin receptors in the caudal brainstem are necessary and sufficient for the anorectic effect of peripherally administered mCPP , 1998, Psychopharmacology.

[26]  J. Terrón,et al.  Effects of the 5-HT receptor antagonists GR127935 (5-HT1B/1D) and MDL100907 (5-HT2A) in the consolidation of learning , 1997, Behavioural Brain Research.

[27]  R. Rosenheck,et al.  A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.

[28]  L. Arvanitis,et al.  Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo , 1997, Biological Psychiatry.

[29]  P. Cowen,et al.  5-HT2C receptor activation decreases appetite and body weight in obese subjects , 1997, Psychopharmacology.

[30]  H. Meltzer,et al.  Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers , 1996, Psychiatry Research.

[31]  R. Littell.  SAS System for Mixed Models , 1996 .

[32]  A. Brown,et al.  m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor. , 1996, Neuroreport.

[33]  A. Sleight,et al.  Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine , 1996, Pharmacology Biochemistry and Behavior.

[34]  D. Mash,et al.  The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. , 1995, Neuroreport.

[35]  H. Meltzer,et al.  Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men , 1995, Psychiatry Research.

[36]  B. Bunney,et al.  Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. , 1995, The Journal of pharmacology and experimental therapeutics.

[37]  D. Sibley,et al.  Clozapine: Selective Labeling of Sites Resembling 5HT6 Serotonin Receptors May Reflect Psychoactive Profile , 1995, Molecular medicine.

[38]  J. Lieberman,et al.  The Behavioral Effect of m-Chlorophenylpiperazine (mCPP) and Methylphenidate in First-Episode Schizophrenia and Normal Controls , 1995, Neuropsychopharmacology.

[39]  M. Grotewiel,et al.  m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts. , 1994, The Journal of pharmacology and experimental therapeutics.

[40]  P. Cowen,et al.  The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers , 1994, Biological Psychiatry.

[41]  L. Siever,et al.  Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine , 1994, Biological Psychiatry.

[42]  K. Cunningham,et al.  Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). , 1994, European journal of pharmacology.

[43]  R. Buchanan,et al.  Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia , 1993, Biological Psychiatry.

[44]  K. Davis,et al.  Serotonin function and treatment response to clozapine in schizophrenic patients. , 1993, The American journal of psychiatry.

[45]  S. Woods,et al.  m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. , 1993, Archives of general psychiatry.

[46]  J. Hsiao,et al.  Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. , 1993, Archives of general psychiatry.

[47]  L. Siever,et al.  Serotonin function in schizophrenia: Effects of meta- chlorophenylpiperazine in schizophrenia patients and healthy subjects , 1992, Psychiatry Research.

[48]  G. Aghajanian,et al.  Excitatory responses to serotonin (5‐HT) in neurons of the rat piriform cortex: Evidence for mediation by 5‐HT1C receptors in pyramidal cells and 5‐HT2 receptors in interneurons , 1991, Synapse.

[49]  R. Kahn,et al.  The MCPP challenge test in schizophrenia: Hormonal and behavioral responses , 1991, Biological Psychiatry.

[50]  S. Woods,et al.  Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects , 1991, Psychiatry Research.

[51]  H. Meltzer.  Role of serotonin in the action of atypical antipsychotic drugs. , 1990, Clinical neuroscience.

[52]  W. Cahn,et al.  Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects , 1990, Psychiatry Research.

[53]  H. Meltzer,et al.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.

[54]  R. Glennon,et al.  Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. , 1989, European journal of pharmacology.

[55]  D. Hoyer,et al.  Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.

[56]  G. Kennett,et al.  Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. , 1989, European journal of pharmacology.

[57]  S. Peroutka,et al.  1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain , 1989, Biological Psychiatry.

[58]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[59]  P. Conn,et al.  Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. , 1987, The Journal of pharmacology and experimental therapeutics.

[60]  J. Csernansky,et al.  Rating scales in research: The case of negative symptoms , 1987, Psychiatry Research.

[61]  J. Leysen,et al.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. , 1985, Molecular pharmacology.

[62]  J. Gerlach,et al.  CLOZAPINE AND HALOPERIDOL IN A SINGLE‐BLIND CROSS‐OVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA , 1974, Acta psychiatrica Scandinavica.

[63]  H. Meltzer,et al.  Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs , 1999, European Archives of Psychiatry and Clinical Neuroscience.

[64]  C. Nemeroff,et al.  New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine , 1998, Depression and anxiety.

[65]  D. Collier,et al.  Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine , 1998, Molecular Psychiatry.

[66]  G. Aghajanian,et al.  The role of serotonin in the pathophysiology and treatment of schizophrenia. , 1997, The Journal of neuropsychiatry and clinical neurosciences.

[67]  Nancy H. Covell,et al.  Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. , 1996, Psychopharmacology bulletin.

[68]  R. Buchanan,et al.  Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. , 1994, The American journal of psychiatry.

[69]  D. Wong,et al.  mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors. , 1992, Life sciences.

[70]  A. Björk,et al.  Amperozide: a new pharmacological approach in the treatment of schizophrenia. , 1990, Pharmacology & toxicology.

[71]  M. Woerner,et al.  Anchoring the BPRS: an aid to improved reliability. , 1988, Psychopharmacology bulletin.